Discover the transformative effects of precision PRP therapy with photobiomodulation on healing and tissue repair for optimal health.

Abstract

In this educational overview, I will guide you through the latest advancements in regenerative medicine, focusing on Platelet-Rich Plasma (PRP) and protein concentrate therapies. We will delve into the science behind optimizing PRP preparations, exploring the critical factors of platelet recovery, concentration, and purity. I’ll share data from my own clinical practice to demonstrate how we achieve high-quality injectables. A significant portion of our discussion will be dedicated to the often-underutilized platelet-poor plasma (PPP) and how we transform it into a powerful protein concentrate rich in anti-inflammatory and regenerative molecules such as Alpha-2-Macroglobulin (A2M) and Interleukin-1 Receptor Antagonist (IL-1ra). Furthermore, we will walk through the pre- and post-procedure patient management protocols essential to maximizing outcomes, including the role of ultrasound-guided injections to enhance precision. Finally, I will touch on the importance of integrative care, including the role of chiropractic adjustments and rehabilitative therapies such as laser therapy, in developing a comprehensive treatment plan for conditions such as osteoarthritis.

Understanding High-Quality Platelet-Rich Plasma (PRP)

As a practitioner dedicated to providing the best possible outcomes for my patients, I consider the quality of the orthobiologics we use paramount. It’s not enough to create “PRP”; we must strive for a product that is potent, pure, and precisely tailored to the patient’s needs.

• Elevated Platelet Recovery: The first quality metric is platelet recovery. This refers to the percentage of platelets we successfully capture from the initial blood draw and concentrate into the final PRP product. In my clinic, we consistently achieve an average platelet recovery of about 83%. It’s important to remember that not all platelets end up in the final PRP layer; some remain in the platelet-poor plasma (PPP), and a small amount is left in the red blood cell (RBC) stack. Maximizing this recovery is key to a potent dose.
• Versatility and Control: A crucial feature of the systems we use. This allows me, as the clinician, to have complete control over the final product. I can precisely dial in the desired volume and determine the composition of the injectate by selectively taking from the buffy coat and the surrounding plasma layers. This control ensures not only simplicity and reproducibility but also the flexibility to create a personalized injectate for each unique clinical situation.
• High Platelet Dose: Ultimately, the goal is to deliver a therapeutic platelet dose. With our system, a single 60 cc blood draw yields an average platelet dose of approximately 8 billion platelets. For those accustomed to thinking in terms of concentration fold, this corresponds to roughly a 10x increase in concentration from the patient’s baseline whole-blood platelet count.

A Closer Look at the Data: From My Clinic to Yours

To illustrate these points, let me share some hematocrit data from a recent sample processed in my clinic.

The patient’s initial whole-blood sample showed a platelet count of 265 (×10³/µL). When multiplied by the 60 cc volume of the blood draw, this gave us a total available platelet count of 15.9 billion in that syringe.

After a single 10-minute centrifugation, we prepared our final injectate: 7 cc of PRP. We then measured the platelet concentration in this final product, and the result was an impressive 2,128 (x10³/?L). Multiplying this by the 7 cc volume gives us a total platelet dose of 14.89 billion platelets contained within that syringe.

For this specific sample, which represents a remarkable 94% platelet recovery rate.

Equally important is what we reduce. Notice the other cell counts:

• Granulocytes (a type of white blood cell): These are significantly reduced from the whole blood baseline. This is important as high concentrations of certain white blood cells can sometimes lead to an undesirable inflammatory flare-up post-injection.
• Red Blood Cells (RBCs): The RBC count in our final PRP sample is less than 0.1. This is critically important, as RBCs can be pro-inflammatory and irritating to the synovial lining of a joint.

In my daily practice, I constantly analyze these factors—dose, white blood cell contribution, and RBC contamination—to ensure I create the most effective and safest injectate for my patients.

The Untapped Potential of Platelet-Poor Plasma (PPP)

Historically, many practitioners would prepare PRP, isolate the platelet-rich layer, and discard the remaining platelet-poor plasma (PPP). We now understand this to be a significant missed opportunity. Current evidence-based research indicates that PPP is a valuable reservoir of proteins and growth factors that play a vital role in combating the degenerative processes underlying conditions like osteoarthritis.

Within PPP, we find:

• A residual number of platelets
• Alpha-2-Macroglobulin (A2M)
• Hepatocyte Growth Factor (HGF)
• Soluble TNF-Receptors (sTNF-R)
• Platelet-Derived Growth Factor (PDGF-BB)
• Interleukin-1 Receptor Antagonist (IL-1ra)
• Epidermal Growth Factor (EGF)

By using a specialized fluid reduction filter—a pre-wetted 15-kilodalton filter—we can dehydrate the PPP sample by about 75%. This process concentrates all these beneficial proteins, creating what we call Protein Concentrate (PC).

This concentration process leads to a significant increase in key molecules:

• Alpha-2-Macroglobulin (A2M) is concentrated to five times its baseline level.
• Soluble TNF-receptors are concentrated at twice their baseline.
• Most clinically significant is the concentration of IL-1ra, which reaches a 100-to-1 ratio relative to the inflammatory cytokine IL-1 beta.
• We also get to scavenge an additional 6 billion platelets that were left behind in the PPP.

The Science Behind Protein Concentrate in Osteoarthritis

Why are these concentrated proteins so important, especially in the context of an arthritic joint?

Alpha-2-Macroglobulin (A2M)

A2M is a very large protein, weighing in at 720 kilodaltons. Because of its size, it cannot easily migrate from the bloodstream into the synovial fluid of a joint on its own. When we inject PC directly into the joint, we are delivering this powerful molecule right where it’s needed.

A2M acts as a “trap” for catabolic (destructive) enzymes. In a chronically inflamed joint, enzymes such as matrix metalloproteinases (MMPs) continuously degrade cartilage. A2M lures these degradative enzymes and irreversibly binds to them, effectively neutralizing them. This creates a powerful negative feedback loop against the chronic inflammation and cartilage breakdown characteristic of osteoarthritis.

Interleukin-1 Receptor Antagonist (IL-1ra)

The cytokine Interleukin-1 (IL-1) is a primary driver of pain and inflammation in osteoarthritis. It binds to receptors on cartilage cells (chondrocytes) and triggers a cascade of inflammatory and degradative events.

IL-1ra is a naturally occurring “antagonist” protein. It has the same shape as IL-1 and binds to the very same receptors on the cell surface. However, when IL-1ra binds, it doesn’t trigger the inflammatory signal. It simply occupies the receptor, physically blocking IL-1 from binding. By injecting a high concentration of IL-1ra into the joint, we effectively reduce ongoing inflammatory signaling, leading to decreased pain and inflammation.

Pre-Procedure Optimization: Setting the Stage for Success

The success of an orthobiologic procedure begins long before the needle enters the skin. My patient consultations for these treatments are thorough and typically last around 36 minutes. This time is essential to establish the correct diagnosis, discuss all available treatment options (including conventional and regenerative approaches), and collaboratively decide on the most viable option for the patient.

Key considerations in our pre-procedure discussion include:

• Steroid Injections: Recent steroid injections can negatively impact the function of cells involved in healing. We need to know the timing of any prior injections.
• Anti-inflammatory Medications (NSAIDs): Most NSAIDs (like ibuprofen or Aleve) interfere with platelet function. I often transition patients to meloxicam, as some newer studies suggest it may be more compatible with orthobiologic treatments. Ideally, patients should stop all NSAIDs for a period before the procedure.
• Supplements: We may recommend specific supplements to help manage pain and inflammation without disrupting platelet function, thereby preparing the body for the procedure.
• Hydration and Nutrition: We instruct patients to begin hydrating well at least two days before their blood draw. A healthy breakfast on the day of the procedure is also recommended. The role of intermittent fasting is still being debated in the research community.
• Financial Transparency: It is crucial to have an open conversation about the cost of the procedure, as it is not typically reimbursed by insurance. For Medicare patients, an Advanced Beneficiary Notice (ABN) must be signed before treatment.

As a functional medicine practitioner, I also perform pre-procedure blood work to assess and optimize the patient’s overall cellular health and metabolism. My goal is to stack the deck in my patient’s favor in every conceivable way to ensure the best possible outcome.

A Look at an Ultrasound-Guided AC Joint Injection

Precision is key. To illustrate this, let’s walk through an acromioclavicular (AC) joint injection. I prefer to perform most shoulder injections with the patient seated, as this position provides better access and efficiency, especially when treating multiple structures. However, one must always be prepared for a potential vasovagal (fainting) response and be ready to quickly move the patient to a lateral decubitus (side-lying) position.

1. Positioning and Technique: I use an out-of-plane technique for the AC joint. The ultrasound transducer is placed on the anterior shoulder, and I mark the injection site. I prefer to enter with the needle from the back, hiding the needle from the patient’s view.
2. Anesthesia and Visualization: After skin prep, the area is anesthetized. I position the ultrasound so the AC joint is directly in the center of the screen.
3. Needle Guidance: I triangulate my entry point. Under ultrasound guidance, the needle tip appears as a bright white dot. I carefully guide it, sometimes sidling up next to the bone before repositioning to drop directly into the joint space.
4. Injection: The PRP should flow freely into the joint space, which can be visualized on the ultrasound screen as the fluid expands the capsule. The AC joint typically contains a small volume of fluid, between 0.6 and 1.1 cc.

My typical workflow for a comprehensive shoulder treatment involves working from back to front. After performing an interscalene nerve block for anesthesia, I’ll start with a posterior glenohumeral (shoulder joint) injection, then move to the AC joint, and finally address tendons like the supraspinatus, subscapularis, and biceps tendon. This systematic approach is highly efficient.

Post-Procedure Care and The Role of Integrative Chiropractic

The care doesn’t stop after the injection. Our post-procedure discussion is just as important as the pre-procedure consult.

For a comprehensive shoulder procedure, our protocol includes:

• Sling: We often place the patient in a sling for one to two days for comfort and as a simple reminder to protect the area.
• Laser Therapy: I am a strong advocate for laser therapy (photobiomodulation), starting the day after the procedure. Laser therapy works by enhancing the availability of ATP, the energy currency of our cells. This accelerates cellular metabolism and the healing process. It also helps with pain management by promoting nitric oxide release. From a safety perspective, photobiomodulation does not carry a risk of tumorigenesis; its mechanism is purely to enhance the body’s natural metabolic and healing capabilities.
• Rehabilitation: For any intratendinous work, a structured rehab protocol is vital. A simple and effective approach is to adapt post-surgical rehab protocols for a similar but less severe injury and start the patient at the week-six mark of that protocol.
• Pain Management: We have patients continue to avoid NSAIDs for several weeks. Near-infrared light, moist heat, and laser therapy are our preferred methods for managing post-injection soreness. We try to avoid ice, as some research suggests it may slow cellular metabolism, but we allow it if it’s the only means of pain relief a patient can tolerate.

As a Doctor of Chiropractic, I see the immense value of integrating chiropractic care into this process. Proper joint mechanics and nervous system function are foundational to healing. Before and after regenerative procedures, chiropractic adjustments can ensure the treated joint and surrounding structures are biomechanically sound, reducing abnormal stresses that could impede healing. Correcting spinal and extremity misalignments can also improve nerve flow and communication, further optimizing the body’s innate healing environment. This integrative approach, combining cutting-edge orthobiologics with foundational chiropractic care and targeted rehabilitation, truly embodies a holistic and patient-centered model of care.

Conclusion

The field of orthobiologics is rapidly evolving, moving beyond simple concepts to a nuanced, evidence-based science of dosing, composition, and application. By focusing on high-quality PRP, harnessing protein concentrates from PPP, and integrating these advanced treatments with precise, ultrasound-guided techniques and comprehensive chiropractic and rehabilitative care, we can offer our patients powerful solutions for pain and dysfunction. It is an exciting time to be in this field, and by staying at the forefront of the research, we can continue to engineer predictable and positive outcomes for those we serve.

References

1. Belk, J. W., Kraeutler, M. J., Houck, D. A., Goodrich, J. A., Dragoo, J. L., & McCarty, E. C. (2021). Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. The American Journal of Sports Medicine, 49(9), 2498–2510. https://doi.org/10.1177/0363546520909397
2. Laudy, A. B., Bakker, E. W., Rekers, M., & Moen, M. H. (2015). Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. British Journal of Sports Medicine, 49(10), 657–672. https://doi.org/10.1136/bjsports-2014-094036
3. Li, M., Zhang, H., Wang, L., Gao, Y., & Li, Z. (2022). Autologous protein solution injections for the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopedic Surgery and Research, 17(1), 161. https://doi.org/10.1186/s13018-022-03051-9
4. Mautner, K., Colberg, R. E., Malanga, G., Borg-Stein, J. P., Harmon, K., Draeger, J., & Bowen, J. E. (2019). Outcomes after Ultrasound-Guided Platelet-Rich Plasma Injections for Chronic Tendinopathy: A Multicenter, Retrospective Review. PM & R: The Journal of Injury, Function, and Rehabilitation, 11(2), 169–179. https://doi.org/10.1016/j.pmrj.2018.06.015
5. Nawrocki, A., & Goldin, M. (2023). Alpha-2-Macroglobulin as a Modulator of Inflammation. International Journal of Molecular Sciences, 24(12), 10300. https://doi.org/10.3390/ijms241210300
6. Welle, M. M., Luyten, F. P., & Spaas, J. H. (2020). Evaluation of in vitro and in vivo effects of a single intra-articular injection of autologous protein solution in horses with osteoarthritis. The American Journal of Sports Medicine, 48(8), 1967-1977. https://doi.org/10.1177/0363546520925251

SEO Tags: Platelet-Rich Plasma, PRP, Protein Concentrate, Orthobiologics, Regenerative Medicine, Osteoarthritis, Dr. Alexander Jimenez, Integrative Chiropractic, Ultrasound-Guided Injections, Functional Medicine, Alpha-2-Macroglobulin, A2M, IL-1ra, Knee Pain, Shoulder Pain, Laser Therapy, Photobiomodulation, Cellular Health